# Roshan Health Hub — Comprehensive Project Health Audit
**Audit date:** 2026-10-19 (Africa/Khartoum)  
**Repository:** https://github.com/crauch2088-source/roshan-health-hub  
**Canonical production URL:** https://roshan-health-hub.vercel.app/  
**Supabase project:** `jewzonxplxhogqrnhosl` (PostgreSQL 17.6)  
**Latest production deployment observed:** READY, source SHA `6e0d1decd1e8adb25d907c2e404bb38bfbeb774a`  
**Live migration ledger observed:** 112 entries; latest `20261019061315_roshan_phase32_medical_certificate_visit_index`

> This is an evidence-based status snapshot, not a claim of 100% certainty. Percentages below are planning estimates with explicit definitions. A feature is not counted as clinically accepted merely because code exists, CI is green, or a deployment is READY.

## 1. Executive assessment

### Current estimated progress

| Measure | Estimate | Meaning |
|---|---:|---|
| Product/software implementation | **~76%** | Core modules and infrastructure exist; remaining gaps are mostly hardening, UX refinement, integration verification, operational readiness and acceptance |
| Technical release readiness | **~65%** | Production deployment and database are available, but source/deployment alignment and remaining operational controls require continued verification |
| Clinical go-live readiness | **~45%** | Not ready to declare safe for routine real-patient operations until end-to-end workflows, role-based acceptance, data/backup recovery, and clinic operating procedures are verified |
| Overall weighted project completion | **~70%** | Weighted assessment across product, security/data, UX, QA, deployment/operations, and real-clinic acceptance |

**Interpretation:** Roshan is a substantial working application, not a blank or merely visual prototype. However, “the app loads” and “the database is healthy” are insufficient to certify a medical-center system for routine operation. The most consequential remaining work is evidence-based closure of release and clinical acceptance gates, not indiscriminate feature expansion.

These percentages are estimates, not instrumented metrics or a line-count calculation. The overall score weights implementation and technical controls more heavily than cosmetic completeness, while the separate clinical-readiness score intentionally remains lower until real workflow acceptance is evidenced.

### Verified strengths

- A real React + TypeScript + Tailwind + TanStack Start application integrated with Supabase and deployed through Vercel.
- Broad application scope: patient registration and records, visits/queue, laboratory, pharmacy/inventory, billing/finance, insurance, administration, reporting and role-aware navigation.
- Automated test coverage includes source-level regression checks, PostgreSQL 17 disposable-database workflows, financial idempotency/concurrency checks, CodeQL, and build/type/lint checks.
- Live Supabase project reports `ACTIVE_HEALTHY` on PostgreSQL 17.6. The observed migration ledger has 112 entries through Phase 32.
- The recorded Phase 31 clinical security cutover is live. Read-back documented removal of direct authenticated write privileges on `lab_order_items` and `medical_certificates`, retention of intended RPC access, and denial of legacy/unlinked RPC overloads.
- The actionable unindexed certificate-visit foreign key finding was addressed by Phase 32 and the index was read back as valid/ready in the recorded audit.
- A PostgreSQL 17 application-schema baseline and synthetic clinical acceptance workflow have been added to the repository and were reported passing on the PR's code-bearing revision.

## 2. Evidence and current system state

### Repository and deployment alignment

- Latest production deployment returned by Vercel: **READY** on `6e0d1decd1e8adb25d907c2e404bb38bfbeb774a`, commit message “docs: close Phase 30 under Phase 31 Contract (#81)”.
- This deployment is associated with the canonical Vercel project `roshan-health-hub`. The canonical alias remains `https://roshan-health-hub.vercel.app/`; the deployment listing confirms the project-specific production deployment, but this audit did not independently exercise every canonical alias route.
- The latest production deployment is not the same commit as the separate clinical workflow/lab-result change `d1fd21eac1221cca100751eadac6ad0fc4607d3c`.
- GitHub compare confirms `d1fd21e...` is **one commit ahead of main** and changes `src/lib/lab-workflow.ts`. PR #82 is closed, but the code commit is not in main. Treat this as a **closed-but-not-merged change requiring an explicit disposition**; do not assume closure means merge.
- The recorded production deploy is READY, and its commit's combined status includes a successful Vercel status. The audit did not find a current complete all-checks summary for the exact production SHA. Historical CI success on an earlier SHA does not prove that every check ran on the latest documentation SHA.

**Required action:** determine whether the closed PR #82 change is intended to ship. If yes, reopen/recreate the change against current main, run all required checks on the exact head, merge under the repository workflow, and then verify production deployment identity. Do not manually cherry-pick or deploy without checking the current branch and test state.

### Database and migration state

- Supabase project: `jewzonxplxhogqrnhosl`; state `ACTIVE_HEALTHY`; PostgreSQL 17.6.
- Live migration ledger: **112 entries**.
- Latest migration: `20261019061315_roshan_phase32_medical_certificate_visit_index`.
- Phase 31 Expand and Contract and Phase 32 are present in the live ledger. **Do not rerun them.**
- The catalog-derived baseline records 56 public tables, 213 constraints, 163 non-constraint indexes, 126 public/private functions, 47 public triggers, 203 public policies, and five views. It is an application-schema baseline with minimal auth compatibility shims, **not** a full export of Supabase-managed schemas/services and **not** a production migration.
- Historical migration replay and full persisted live-SQL hash parity are not yet established. One environment-specific identity-link migration is intentionally redacted, and the original historical bootstrap was previously documented as missing. Keep this limitation visible until a safe, reproducible bootstrap/reconciliation strategy is proven.

### Security and performance advisor state

Live advisor reads on 2026-10-19 returned:

| Finding | Count | Assessment / response |
|---|---:|---|
| Authenticated-callable `SECURITY DEFINER` functions | 22 | Warnings require contextual review. Recorded triage found fixed empty `search_path`, no `anon` EXECUTE, and intended authenticated RPC usage; this is not proof that every function is fully adversarially reviewed. Do not revoke them in bulk. |
| `pg_trgm` installed in `public` | 1 | Defer relocation until operator classes, indexes and extension dependencies are mapped and tested. |
| Leaked-password protection disabled | 1 | Documented as plan-gated on the connected tier. Do not claim enabled; avoid unsafe workarounds or unapproved paid upgrades. |
| Unused-index suggestions | 89 | Informational in a very low-traffic/prelaunch system. Do not drop in bulk; correlate with query plans and workload after real use. |
| Unindexed certificate `visit_id` FK | 0 in latest recorded triage | Phase 32 added the index and read-back reported it valid/ready. |

The 22 SECURITY DEFINER findings are not automatically vulnerabilities: several are deliberately callable application RPCs. Conversely, the existence of a fixed search path and a permission-helper marker does not alone prove every authorization branch correct. Any further changes must be function-specific and supported by tests.

### Test and acceptance evidence

**Reported as implemented / exercised in CI**
- Install, security audit, TypeScript typecheck, lint, production build and repository guard tests.
- PostgreSQL 17 disposable-database migration/behavior checks.
- Finance idempotency and concurrency regression workflows.
- Phase 31/32 regression for clinical RPC behavior and the certificate visit index.
- A synthetic clinical workflow test using receptionist, doctor, lab technician and pharmacist JWT identities, including partial lab save, idempotent resave, atomic visit/queue completion, visit-linked certificate serial generation, pharmacist rejection, and cancelled-visit rejection. The workflow is intended for isolated CI and rolls back its synthetic rows.
- The PR #79 summary reports 14/14 CI jobs and 7/7 PR-triggered workflows passing on its code-bearing revision. Do not generalize that result to unrelated or later commits without exact-SHA check evidence.

**Still not equivalent to completed real-world acceptance**
- Authenticated browser end-to-end testing of patient registration → visit/queue → lab order/sample/result/verification/completion → invoice/payment/pharmacy as applicable → medical certificate.
- Doctor-role certificate issuance in an isolated test identity.
- Verification of the actual DOM disabled state for the New Visit Save button where prior browser observation conflicted with tracked source.
- Confirmation that the exact latest main source is deployed and smoke-tested through the canonical production alias.
- Complete visual/accessibility and business-logic review of every route, popup, permission state and mobile screen.
- Backup/restore or disaster-recovery evidence and documented clinic-side operating procedures.

Clinical E2E was previously deferred at the user's direction. It must remain marked **open** until deliberately resumed and passed; this report does not perform clinical transactions in production.

## 3. Workstream completion estimate

The following values are planning estimates, not direct repository analytics.

| Workstream | Estimated completion | Remaining work |
|---|---:|---|
| Core application and modules | 82% | Validate all critical paths and edge cases; close remaining feature gaps against the current product brief |
| Database, RLS and financial/clinical write controls | 82% | Complete targeted adversarial function review, preserve migration parity/replay caveats, verify backup/recovery |
| UX, mobile navigation and visual consistency | 68% | Full screen-by-screen audit, accessibility, Arabic RTL/English LTR, interaction consistency, reduce unnecessary clicks |
| Automated test infrastructure | 78% | Exact-main check reconciliation, coverage for remaining high-risk workflows, keep isolated clinical acceptance passing |
| Deployment and operational controls | 62% | Prove canonical alias/source alignment, post-deploy smoke tests, monitoring and recovery runbook |
| Clinical acceptance and clinic readiness | 35% | Role-based browser E2E, clinical sign-off, medicine/lab catalog validation, printer and real workflow rehearsal, staff procedures |

## 4. Critical remaining work, in priority order

### P0 — release integrity and clinical safety gates

1. **Resolve closed PR #82 / unmerged code.** Confirm intent, re-open/recreate if wanted, run CI against current main, merge only after passing, and verify the deployed SHA. The lab-result mapper affects clinical interpretation; review its boundary cases before release, including explicit zero-valued reference limits, missing limits, critical flags, numeric-vs-text/coded values and legacy callers.
2. **Reconcile main, production and CI.** Record the exact main SHA, exact production SHA, canonical alias target and exact-SHA CI status in one place. A READY deployment can be stale; CI and deployment are separate release gates.
3. **Run isolated clinical E2E.** Use synthetic identities with receptionist, doctor, lab and pharmacy roles in disposable PostgreSQL 17/browser environment. Do not create artificial patient/financial transactions in production.
4. **Check release-critical RPCs and permissions.** Match each browser call to its exact signature and role/branch guards. Keep legacy unsafe overloads denied. Do not perform blanket SECURITY DEFINER revocations.
5. **Verify New Visit save behavior.** Inspect the actual rendered DOM state and query result/permission error handling before changing implementation.

### P1 — security, resilience and operations

6. Complete targeted review of remaining SECURITY DEFINER bodies and frontend call sites; add allow/deny tests for role, branch, soft-delete and state-transition boundaries.
7. Document migration reconciliation limits and build a reproducible fresh-environment bootstrap path that does not execute the redacted historical migration or mistake the catalog baseline for a production migration.
8. Establish evidence for backups, restore procedure, account recovery, least-privilege access and secret rotation/history review. Current secret scanning and push protection are reported enabled with zero open alerts, but historical credential exposure is not proven absent.
9. Recheck Better Stack monitor `5086672` after the canonical target correction; HTTP uptime does not prove login, database or clinical workflows.
10. Review Dependabot/dependency alert coverage. A repository issue records vulnerability alerts as disabled and the connected tool's attempted read/update as unavailable/403. Resolve through supported repository settings when access allows; do not claim it is enabled.

### P2 — product quality and clinic readiness

11. Perform a route-by-route UX audit of clinical, lab, pharmacy, finance, insurance, reports, settings and administration. Record screenshot/viewport, role, result, defect severity and regression test for each finding.
12. Confirm Arabic RTL and English LTR, small-screen behavior on the user's phone class, keyboard/accessibility basics, error/loading/empty states and print layouts.
13. Review prescription and laboratory catalogs with clinical governance: units, reference intervals, age/sex-specific ranges where applicable, critical values, dosage/formulation/instructions, allergy handling and medication safety. Do not auto-prescribe from unvalidated templates.
14. Rehearse the real clinic's daily sequence with staff: reception, queue, consultation, laboratory, pharmacy, billing, receipts, end-of-day cash reconciliation and exception handling.
15. Define operational ownership: who creates users/roles, edits catalogs, handles outages, performs backups, reconciles payments and escalates a suspected privacy/security incident.

## 5. Timeline to gain the next 10 percentage points

The “next 10%” means moving the **overall weighted estimate from about 70% to about 80%**, not completing 10% of the remaining code. It is a planning target, not a guarantee. Estimates assume focused work, connected tools remain available, no paid plan is required, and the required test identity/environment can be accessed.

| Stage | Expected effort | Target outcome | Exit evidence |
|---|---:|---|---|
| A. Repository/deployment reconciliation and PR #82 disposition | 0.5–1 day | Exact main/production/PR state made consistent; code decision documented | Commit comparison, exact-SHA checks, merge/deploy state recorded |
| B. Clinical E2E in isolated environment | 1–2 days | Critical patient/visit/lab/certificate flow tested without production records | PostgreSQL 17 acceptance + role-based browser run; failures tracked/fixed |
| C. Focused security/authorization closure | 1–2 days | High-risk RPC paths reviewed and gaps fixed only where proven | Allow/deny regression tests, live grants read-back if a migration is justified |
| D. Operational release checks | 0.5–1 day | Canonical deployment, monitor, rollback/recovery and environment status reconciled | Production SHA/alias verification, smoke test and monitoring evidence |
| E. Highest-severity UX fixes and regression | 1–2 days | Most important navigation/form/accessibility defects closed | Before/after evidence and passing CI |

**Expected calendar duration:** approximately **5–8 focused working days** (often 1–2 calendar weeks depending on CI/deployment limits and access to the isolated browser/test identity). Work can overlap where tasks are independent. If the free Vercel deployment quota or test-environment access blocks progress, calendar duration will increase; do not bypass limits or create duplicate paid infrastructure.

A sensible first checkpoint is the end of Stage B: if critical workflows pass and the source/deployment discrepancy is closed, the overall score can reasonably be reassessed. The percentage should only rise when acceptance evidence is added, not when documentation is written.

## 6. Expected blockers and mitigations

| Blocker | Risk | Recommended mitigation |
|---|---|---|
| Closed PR is ahead of main | Intended lab-result fix may not ship | Explicitly re-open/recreate against current main; exact-SHA CI; merge and verify deployment |
| Vercel free-tier build-rate limit | Delays release validation | Use already available preview/CI evidence, wait for quota reset, avoid forced deployments, duplicate projects or upgrades without approval |
| No isolated doctor-role browser identity | Clinical acceptance remains unproven | Create/use a least-privilege synthetic identity in an isolated free test setup; keep production data untouched |
| Historical migration/bootstrap gap | New environments may not replay cleanly | Treat baseline as a CI fixture only; document redacted migration; create a separately reviewed bootstrap/reconciliation process |
| SECURITY DEFINER warnings | Risk of either missed authorization flaw or breaking valid RPCs | Function-by-function source + grant + caller review, then positive/negative regression; no blanket revocation |
| Low production traffic / 89 unused-index hints | False-positive performance cleanup | Preserve indexes until workload/query-plan evidence supports a specific removal |
| Plan-gated leaked-password protection | Authentication hardening gap | Record accepted limitation; evaluate supported plan/settings options only if needed and authorized |
| Historical secret exposure unknown | Public history may differ from current tree | Review provider alerts/history with secret values hidden; rotate any verified exposed credential at the provider first |
| UI review scope is large | Hidden role/viewport/empty-state defects | Build a route/role/viewport matrix and fix by clinical/financial risk, not visual preference alone |
| Clinic procedures/catalogs not formally accepted | Technically working app may still be unsafe operationally | Staff rehearsal, clinician-approved catalogs, printer checks, end-of-day finance and downtime procedures |

## 7. Definition of “ready for initial clinic operation”

Do not call the project fully ready until each applicable item is evidenced:

- [ ] Current main, production deployment and canonical domain are reconciled to the intended release.
- [ ] Exact release SHA has all required CI/security/build checks green.
- [ ] Isolated role-based clinical E2E passes, including lab result save/completion and visit-linked certificate issuance.
- [ ] Patient, visit, queue, lab, prescription, invoice/payment, pharmacy and audit flows enforce role and branch rules.
- [ ] High-risk RPCs have targeted authorization and invalid-state tests; legacy overloads remain denied.
- [ ] Backup/restore and incident recovery procedure are tested or explicitly accepted as a documented launch limitation.
- [ ] Arabic/English layout, phone behavior, printing and error/empty/loading states are checked on critical routes.
- [ ] Staff accounts and least-privilege permissions are reviewed; no shared admin credentials for routine use.
- [ ] Medicine/test catalogs, reference ranges, critical flags, dosage templates and printable forms receive clinical sign-off.
- [ ] Monitoring is confirmed against the canonical domain, with the limitation that uptime is not workflow health.
- [ ] Clinic staff rehearse the daily patient flow, payment reconciliation and downtime workaround.
- [ ] Remaining known limitations are listed, owned and consciously accepted before live patient use.

## 8. Audit limitations and confidence

This report combines direct repository file/commit comparisons, Vercel deployment listing, Supabase project/migration/advisor reads, and the existing repository audit evidence. It did **not** conduct a new full browser session for every route, execute clinical transactions in production, perform a disaster-recovery restore, or independently re-run every CI job from this report. Accordingly:

- Deployment READY is not clinical acceptance.
- Migration count is not proof of complete historical replay or source-hash parity.
- Advisor warnings are signals to investigate, not proof of exploitation.
- “No open secret alerts” is not proof that no secret was ever exposed.
- Percentages and timelines are estimates and must be revised as exact evidence changes.

## 9. Source-of-truth documents and evidence

- [Master plan](MASTER_PLAN.md)
- [Plugin/tooling map](PLUGIN_TOOLING_MAP.md)
- [Database migration reconciliation](DB_MIGRATION_RECONCILIATION.md)
- [Security Advisor triage (2026-10-19)](SECURITY_DEFINER_ADVISOR_TRIAGE_2026-10-19.md)
- [Authenticated production route QA (2026-10-18)](AUTHENTICATED_PRODUCTION_ROUTE_QA_2026-10-18.md)
- [PR #79 — PostgreSQL 17 baseline and isolated clinical acceptance](https://github.com/crauch2088-source/roshan-health-hub/pull/79)
- [PR #82 — clinical query error isolation and typed lab-result mapping](https://github.com/crauch2088-source/roshan-health-hub/pull/82)
- [Latest observed production deployment](https://vercel.com/roshan45/roshan-health-hub/8dCbmC2y5NVdnBNi72VBf3eEWzjW)
- [Supabase extension-in-public remediation guidance](https://supabase.com/docs/guides/database/database-linter?lint=0014_extension_in_public)
- [Supabase SECURITY DEFINER remediation guidance](https://supabase.com/docs/guides/database/database-linter?lint=0029_authenticated_security_definer_function_executable)
- [Supabase unused-index guidance](https://supabase.com/docs/guides/database/database-linter?lint=0005_unused_index)

---

## Immediate next action

Resolve the closed-but-unmerged PR #82 decision, then reconcile exact main/production SHA and run the isolated clinical E2E gate. These are higher-value release steps than starting another broad feature batch.
